| Literature DB >> 29507793 |
Andrea Bianco1, Tullio Valente2, Maria Luisa De Rimini3, Giacomo Sica2, Alfonso Fiorelli4.
Abstract
Malignant pleural mesothelioma (MPM) is a tumour which, despite progress in diagnostic procedures and biomolecular research, has poor prognosis. Symptoms reflect extension of disease and include shortness of breath and chest pain. Unexplained pleural effusion and pleural pain in patients exposed to asbestos should raise the suspicion of MPM. MPM diagnosis requires imaging procedures X-ray and computed tomography (CT) scans; magnetic resonance imaging (MRI) better defines the extension of the tumor while PET scanning provides additional information on metabolic activity, metastases, and response to treatment. Thoracoscopic biopsy remains the most appropriate procedure for definitive diagnosis of mesothelioma. Multimodality treatment including surgery, chemotherapy and radiotherapy has been associated with a better survival in selected patients. Clinical translational research including new approaches targeting immune-checkpoints is opening new horizons which may lead to personalised treatments.Entities:
Keywords: Pleural mesothelioma; clinical diagnosis; malignant pleural mesothelioma (MPM)
Year: 2018 PMID: 29507793 PMCID: PMC5830561 DOI: 10.21037/jtd.2017.10.09
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895